PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20551596-2 2010 HGF is produced by stromal cells, and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor, c-Met. Tyrosine 143-151 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 185-190 20432459-7 2010 Furthermore, we found that Sorafenib induced c-Met phosphorylation at Tyr-1349 but not Tyr-1234, which is probably mediated by inhibition of receptor tyrosine phosphatase density enhanced phosphatase-1 (DEP-1). Tyrosine 70-73 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 45-50 20623641-3 2010 EGCG acted at the level of preventing phosphorylation of tyrosines 1234/1235 in the kinase domain of the c-Met receptor without effecting dimerization. Tyrosine 57-66 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 105-110 19375427-3 2009 The bioassay utilizes PC-3 cells that respond to treatment with hepatocyte growth factor (HGF) with phosphorylation of tyrosine residues on c-Met, the receptor for HGF. Tyrosine 119-127 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 140-145 19240370-9 2008 In A549 and H1838 cell lines, HGF (40 ng/ml) and EGF (5 ng/ml) induced synergistic phosphorylation on c-Met (Tyr 1003/1230/1234/1235). Tyrosine 109-112 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 102-107 19121849-4 2009 The expression levels of 2 tyrosine residues of hepatocyte growth factor receptor/c-Met (pY1234/1235 and pY1349) were examined immunohistochemically in 133 specimens with nonmetastatic bladder cancer. Tyrosine 27-35 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 48-81 19121849-4 2009 The expression levels of 2 tyrosine residues of hepatocyte growth factor receptor/c-Met (pY1234/1235 and pY1349) were examined immunohistochemically in 133 specimens with nonmetastatic bladder cancer. Tyrosine 27-35 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 82-87 19403923-3 2009 Monitoring the phosphorylation status of relevant tyrosine residues provides an important method of assessing c-Met kinase activity. Tyrosine 50-58 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 110-115 17689924-9 2007 Furthermore, pretreatment of LPA attenuated HGF-induced c-Met tyrosine phosphorylation and downstream signaling, such as Akt kinase phosphorylation and cell motility. Tyrosine 62-70 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 56-61 18046719-3 2007 We found that HGF enhanced Cpd 5-induced c-Met phosphorylation at Tyr-1349, a binding site for Gab1, resulting in increased c-Met binding to Gab1, and induced strong and prolonged Gab1 tyrosine phosphorylation. Tyrosine 66-69 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 41-46 18046719-3 2007 We found that HGF enhanced Cpd 5-induced c-Met phosphorylation at Tyr-1349, a binding site for Gab1, resulting in increased c-Met binding to Gab1, and induced strong and prolonged Gab1 tyrosine phosphorylation. Tyrosine 66-69 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 124-129 17689859-4 2007 CHM-1 significantly inhibited tyrosine autophosphorylation of c-Met induced by HGF. Tyrosine 30-38 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 62-67 16724983-4 2006 RESULTS: The c-Met tyrosine phosphorylation in PLC/PRF/5 hepatoma cells was increased by treatment with 20 ng/mL hepatocyte growth factor (HGF), and extracellular signal-regulated kinase (ERK) was also activated. Tyrosine 19-27 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 13-18 17062641-3 2006 The phosphorylated 145-kDa protein was identified as the beta-subunit of c-Met/hepatocyte growth factor (HGF) receptor, p145(met), in which tyrosine residues 1003, 1234, and 1235 were phosphorylated. Tyrosine 140-148 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 79-118 16227408-3 2005 Among the five hepatocellular carcinoma and one normal human liver cell lines we analyzed, c-Met was highly expressed and constitutively tyrosine phosphorylated in only MHCC97-L and HCCLM3 hepatocellular carcinoma cells. Tyrosine 137-145 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 91-96 16415345-3 2006 In hepatocytes cultured at a sparse cell density, HGF stimulation induced prolonged c-Met tyrosine phosphorylation for over 5 h and a marked mitogenic response. Tyrosine 90-98 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 84-89 16415345-4 2006 In contrast, HGF stimulation induced transient c-Met tyrosine phosphorylation in <3 h and failed to induce mitogenic response in hepatocytes cultured at a confluent cell density. Tyrosine 53-61 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 47-52 16415345-6 2006 The mitogenic response to HGF was associated with the duration of c-Met tyrosine phosphorylation even in the sparse cells. Tyrosine 72-80 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 66-71 16415345-8 2006 LAR and c-Met were associated, and purified LAR dephosphorylated tyrosine-phosphorylated c-Met in in vitro phosphatase reactions. Tyrosine 65-73 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 8-13 16415345-8 2006 LAR and c-Met were associated, and purified LAR dephosphorylated tyrosine-phosphorylated c-Met in in vitro phosphatase reactions. Tyrosine 65-73 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 89-94 16415345-9 2006 Furthermore, antisense oligonucleotides specific for LAR mRNA suppressed the expression of LAR, allowed prolonged c-Met tyrosine phosphorylation, and led to acquisition of a mitogenic response in hepatocytes even under the confluent condition. Tyrosine 120-128 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 114-119 16291834-9 2006 PPAR-gamma agonists also activated c-met receptor tyrosine phosphorylation, induced Smad transcriptional co-repressor TG-interacting factor expression, and blocked TGF-beta/Smad-mediated gene transcription in mesangial cells. Tyrosine 50-58 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 35-40 15075332-1 2004 Previous studies indicated that treatment of cells with 12-O-tetradecanoylphorbol-13-acetate induced phosphorylation of Ser-985 at the juxtamembrane of c-Met, the receptor tyrosine kinase for hepatocyte growth factor (HGF), and this was associated with decreased tyrosine phosphorylation of c-Met. Tyrosine 172-180 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 152-157 15839837-7 2005 This hepsin-processed HGF induced c-Met receptor tyrosine phosphorylation in SKOV-3 ovarian cancer cells, indicating that the hepsin-cleaved HGF is biologically active. Tyrosine 49-57 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 34-39 15588784-4 2004 Recombinant HGF administered intravenously was distributed primarily to the liver and induced c-Met tyrosine phosphorylation in liver tissues. Tyrosine 100-108 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 94-99 15301554-2 2004 We present a comparative thermodynamic analysis of functionally active dimeric and functionally inactive monomeric soluble analogues of the c-MET RTK, which clearly reveal that oligomerization regulates the binding affinity and binding kinetics of the kinase toward ATP and tyrosine-containing peptide substrates. Tyrosine 274-282 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 140-145 15301554-6 2004 Significantly, under equilibrium binding conditions, the oligomeric phosphorylated kinase showed a significantly lower dissociation constant (K(d,dimer) = 11 microM) for a tyrosine-containing peptide derived from the C-terminal tail of the c-MET RTK when compared to the phosphorylated monomeric kinase cytoMET (K(d,monomer) = 140 microM). Tyrosine 172-180 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 240-245 16237757-4 2005 RESULTS: Immunoprecipitation analysis revealed that 10 micromol/L LPA induced tyrosine phosphorylation of c-Met and EGFR in LoVo cells within a few minutes. Tyrosine 78-86 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 106-111 16237757-5 2005 We found that c-Met tyrosine phosphorylation induced by LPA was not attenuated by pertussis toxin or a matrix metalloproteinase inhibitor, in marked contrast to the results for EGFR. Tyrosine 20-28 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 14-19 15530853-7 2004 Immunoprecipitation analysis revealed that LPA induced transient tyrosine phosphorylation of c-Met in LPA2-expressing cells, which suggests that the transactivation of c-Met by LPA causes a cooperative migratory response with HGF to these cells. Tyrosine 65-73 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 93-98 15530853-7 2004 Immunoprecipitation analysis revealed that LPA induced transient tyrosine phosphorylation of c-Met in LPA2-expressing cells, which suggests that the transactivation of c-Met by LPA causes a cooperative migratory response with HGF to these cells. Tyrosine 65-73 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 168-173 15265705-5 2004 In the present study, Treatment of ECV304 endothelial cells with HGF resulted in tyrosine phosphorylation of c-Met and activation of SPK in a concentration-dependent manner. Tyrosine 81-89 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 109-114 15288476-7 2004 Consequently, tyrosine autophosphorylation of the c-met induced by HGF was inhibited in these cells by SU5416 in a dose-dependent manner. Tyrosine 14-22 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 50-55 15075332-7 2004 Addition of HGF to A549 cells in culture induced c-Met tyrosine phosphorylation, the result being mitogenic response and cell scattering. Tyrosine 55-63 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 49-54 15075332-8 2004 In contrast, in the presence of H(2)O(2) stress, HGF-dependent tyrosine phosphorylation of c-Met was largely suppressed with a reciprocal relationship to Ser-985 phosphorylation, and this event was associated with abrogation of cellular responsiveness to HGF. Tyrosine 63-71 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 91-96 14559814-13 2003 The JM mutations also altered the c-MET RTK signaling, resulting in preferentially increased constitutive tyrosine phosphorylation of various cellular proteins, including the key focal adhesion protein paxillin on tyrosine residue Y31 (first CRKL-binding site), correlating with increased motility. Tyrosine 106-114 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 34-39 15187417-6 2004 Although the peak level of c-Met phosphorylation was not different in both transfectants, the level of tyrosine phosphorylation of c-Met decreased more rapidly in the GnT-III transfectants than in the mock transfectants. Tyrosine 103-111 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 131-136 14559814-13 2003 The JM mutations also altered the c-MET RTK signaling, resulting in preferentially increased constitutive tyrosine phosphorylation of various cellular proteins, including the key focal adhesion protein paxillin on tyrosine residue Y31 (first CRKL-binding site), correlating with increased motility. Tyrosine 214-222 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 34-39 12520544-5 2003 Upon HGF/SF stimulation, the c-Met receptor is tyrosine-phosphorylated which is followed by the recruitment of a group of signaling molecules and/or adaptor proteins to its cytoplasmic domain and its multiple docking sites. Tyrosine 47-55 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 29-34 12845672-6 2003 NK4 also suppressed HGF/SF- and MRC5-induced tyrosine phosphorylation of the HGF/SF receptor Met as assessed by immunoprecipitation. Tyrosine 45-53 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 77-92 12883706-4 2003 HGF/SF stimulation also enhanced the tyrosine phosphorylation of HGF receptors (c-Met) and focal adhesion kinase (FAK) on SAS cells, but C3 completely inhibited the phosphorylation of FAK. Tyrosine 37-45 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 80-85 12594808-0 2003 Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. Tyrosine 138-146 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 21-33 12594808-0 2003 Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. Tyrosine 138-146 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 34-39 12594808-6 2003 Whether the resultant alteration in c-Met would cascade as biologically usable signals upon HGF ligation was traced by receptor tyrosine phosphorylation analysis and mitogen activated protein kinase (MAP kinase or MAPK) activity assay. Tyrosine 128-136 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 36-41 12594808-11 2003 The radiation-increased expression of c-Met could transform into magnifying receptor tyrosine phosphorylation reaction and MAP kinase activity once the ligand was added, fairly corresponding with alteration in the receptor. Tyrosine 85-93 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 38-43 12611639-3 2002 c-Met contains an external semaphorin-like domain, a cytoplasmic juxtamembrane domain, tyrosine kinase domain and multiple tyrosines that bind to adapter molecules. Tyrosine 123-132 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 0-5 12856716-0 2003 Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin. Tyrosine 87-95 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 14-19 12856716-4 2003 The high metastatic cells express a c-Met that is constitutively tyrosine phosphorylated, they have increased colony formation, and are minimally responsive to HGF relative to the parental cells. Tyrosine 65-73 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 36-41 12856716-5 2003 Tyrosine-phosphorylated beta-catenin was constitutively associated with c-Met in the more metastatic cells, but was inducible only after HGF addition in the less metastatic cells. Tyrosine 0-8 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 72-77 12500176-6 2002 Tyrosine phosphorylation of c-met and morphological studies was performed on vitreous treated ARPE-19 cells. Tyrosine 0-8 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 28-33 12500176-11 2002 ARPE-19 cells treated with vitreous from the 24 h post-surgical eyes, but not with control vitreous or IL-1beta, showed morphological changes and tyrosine phosphorylation of c-met. Tyrosine 146-154 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 174-179 12500177-7 2002 Tyrosine phosphorylation of the HGF receptor (HGFR or c-met) and beta-catenin was determined by immunoprecipitation and western blot analysis. Tyrosine 0-8 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 32-44 12500177-7 2002 Tyrosine phosphorylation of the HGF receptor (HGFR or c-met) and beta-catenin was determined by immunoprecipitation and western blot analysis. Tyrosine 0-8 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 46-50 12500177-7 2002 Tyrosine phosphorylation of the HGF receptor (HGFR or c-met) and beta-catenin was determined by immunoprecipitation and western blot analysis. Tyrosine 0-8 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 54-59 12500177-11 2002 HGF induced a MAP kinase dependent ARPE-19 cell migration, which is accompanied with a transient increase of c-jun expression and concomitant increases of MAP kinase activity, tyrosine phosphorylation of HGFR and beta-catenin, increased cytosolic levels of beta-catenin, and transactivation activity of beta-catenin. Tyrosine 176-184 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 204-208 12500177-12 2002 Tyrosine phosphorylation of HGFR and beta-catenin occurs in the primary or passaged RPE cultures or proliferative ARPE-19 cells, but not freshly isolated RPE or differentiated ARPE-19 cells. Tyrosine 0-8 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 28-32 12611639-5 2002 Utilizing unique phospho-specific antibodies generated against various tyrosines of c-Met, we show that Y1003 (binding site for c-Cbl and a negative regulatory site), Y1313 (binding site for PI3K), Y1230/Y1234/Y1235 (autophosphorylation site), Y1349 (binding site for Grb2), Y1365 (important in cell morphogenesis) are phosphorylated in response to HGF (40 ng/ml, 7.5 min) in H69 cells. Tyrosine 71-80 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 84-89 12183053-0 2002 CD44 stimulation by fragmented hyaluronic acid induces upregulation and tyrosine phosphorylation of c-Met receptor protein in human chondrosarcoma cells. Tyrosine 72-80 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 100-105 12183053-2 2002 Since HGF/SF receptor, c-Met, is expressed by tumor cells, and since stimulation of CD44, a transmembrane glycoprotein known to bind hyaluronic acid (HA) in its extracellular domain, is involved in activation of c-Met, we have studied the effects of CD44 stimulation by ligation with HA upon the expression and tyrosine phosphorylation of c-Met on human chondrosarcoma cell line HCS-2/8. Tyrosine 311-319 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 212-217 12183053-3 2002 The current study indicates that (a) CD44 stimulation by fragmented HA upregulates expression of c-Met proteins; (b) fragmented HA also induces tyrosine phosphorylation of c-Met protein within 30 min, an early event in this pathway as shown by the early time course of stimulation; (c) the effects of HA fragments are critically HA size-dependent. Tyrosine 144-152 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 172-177 12183053-2 2002 Since HGF/SF receptor, c-Met, is expressed by tumor cells, and since stimulation of CD44, a transmembrane glycoprotein known to bind hyaluronic acid (HA) in its extracellular domain, is involved in activation of c-Met, we have studied the effects of CD44 stimulation by ligation with HA upon the expression and tyrosine phosphorylation of c-Met on human chondrosarcoma cell line HCS-2/8. Tyrosine 311-319 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 212-217 12115601-5 2002 c-Met is signaling competent in DC since it is effectively tyrosine phosphorylated in response to SF ligand. Tyrosine 59-67 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 0-5 11557528-5 2001 HGF also stimulated expression and tyrosine phosphorylation of c-Met and Gab-1 as well as protein kinase C (PKC)-alpha expression. Tyrosine 35-43 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 63-68 11839685-9 2002 Some of these tyrosine-phosphorylated bands were identified as the focal adhesion proteins paxillin, FAK, PYK2, and the c-Met receptor itself. Tyrosine 14-22 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 120-125 11745410-0 2001 Ganglioside GD1a inhibits HGF-induced motility and scattering of cancer cells through suppression of tyrosine phosphorylation of c-Met. Tyrosine 101-109 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 129-134 11745410-6 2001 The level of tyrosine phosphorylation of c-Met after HGF stimulation in FBJ-S1 cells, GD1a-pretreated FBJ-LL cells and a GD1a-expressing transfectant was significantly lower than in FBJ-LL cells and a mock-transfectant. Tyrosine 13-21 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 41-46 11745410-7 2001 These findings suggested that GD1a inhibits the HGF-induced motility of FBJ-LL cells through suppression of tyrosine phosphorylation of c-Met. Tyrosine 108-116 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 136-141 11267961-17 2001 The tyrosine phosphorylation of EGFR or c-met by VK3 activated the Ras signaling pathway. Tyrosine 4-12 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 40-45 11290563-6 2001 The addition of HGF in the culture medium stimulated tyrosine phosphorylation of c-MET. Tyrosine 53-61 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 81-86 11278639-3 2001 Upon HGF binding, several tyrosines within the intracellular domain of its receptor, c-Met, become phosphorylated and mediate the binding of effector proteins, such as Grb2. Tyrosine 26-35 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 85-90 11254878-3 2001 Furthermore, continued exposure to this motogen increased the level of co-precipitations between the E-cadherin/catenin complex with c-Met, and also increased tyrosine phosphorylation of c-Met. Tyrosine 159-167 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 187-192 10702398-6 2000 In three cases of sarcoma with high HGF receptor expression by Western blotting, we found indications of a short 85-kd N-terminally truncated HGF receptor that was tyrosine phosphorylated and located in the cytoplasm. Tyrosine 164-172 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 142-154 10759945-10 2000 When c-met staining was compared with E-cadherin and beta-catenin expression, a statistical significant correlation was established between c-met immunoreactivity and abnormal beta-catenin expression (P = 0.025) suggesting possible involvement of c-met in the downregulation of the E-cadherin-catenin complex, possibly through tyrosine phosphorylation of beta-catenin. Tyrosine 327-335 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 140-145 10759945-10 2000 When c-met staining was compared with E-cadherin and beta-catenin expression, a statistical significant correlation was established between c-met immunoreactivity and abnormal beta-catenin expression (P = 0.025) suggesting possible involvement of c-met in the downregulation of the E-cadherin-catenin complex, possibly through tyrosine phosphorylation of beta-catenin. Tyrosine 327-335 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 140-145 11123423-2 2000 It induced protein tyrosine phosphor-ylation of hepatocyte growth factor (HGF) receptor (c-Met) or epidermal growth factor receptor (EGFR), which increased progressively to a maximum level at 30 min in Panc-1 cells. Tyrosine 19-27 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 48-94 10520577-0 1999 Presence and tyrosine phosphorylation of c-met receptor in human sperm. Tyrosine 13-21 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 41-46 11014955-6 2000 c-MET receptor was expressed and also tyrosine-phosphorylated constitutively in these cell lines by Western blotting. Tyrosine 38-46 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 0-5 10520577-7 1999 The c-met receptor was tyrosine phosphorylated/autophosphorylated during capacitation and in the cell-free in vitro kinase assay. Tyrosine 23-31 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 4-9 10430176-5 1999 In both lines we observed that the overexpressed and constitutively tyrosine phosphorylated HGF receptor maintained biochemical responsiveness to the ligand. Tyrosine 68-76 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 92-104 10520577-8 1999 Incubation of human sperm with hepatocyte growth factor (HGF) or MAb2 to c-met receptor enhanced the degree of tyrosine phosphorylation/autophosphorylation of the c-met receptor up to 5.1-fold. Tyrosine 111-119 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 73-78 10520577-8 1999 Incubation of human sperm with hepatocyte growth factor (HGF) or MAb2 to c-met receptor enhanced the degree of tyrosine phosphorylation/autophosphorylation of the c-met receptor up to 5.1-fold. Tyrosine 111-119 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 163-168 10520577-9 1999 These findings indicate that the c-met receptor is present in the acrosomal region of human sperm cell and is tyrosine phosphorylated, which is enhanced by HGF and the receptor antibody. Tyrosine 110-118 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 33-38 9705867-5 1998 Tyrosine phosphorylation of c-Met was constitutively found in 72 hour RPE cultures and could be rapidly induced in serum-starved cells by concentrated RPE supernatants. Tyrosine 0-8 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 28-33 10763917-5 1999 HGF stimulated the motility of Hep3B, HepG2, and Huh-7 cells in a dose-dependent manner in association with tyrosine phosphorylation of c-Met and activation of phosphatidylinositol 3-kinase (PI3-K). Tyrosine 108-116 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 136-141 10763917-9 1999 These results indicate that HGF stimulates the migration of HCC cells through the tyrosine phosphorylation of c-Met via activation of PI3-K. Tyrosine 82-90 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 110-115 9888438-4 1999 The expression and tyrosine phosphorylation of HGFR protein was evaluated in RPE cells by immunoprecipitation and western blot analysis. Tyrosine 19-27 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 47-51 9888438-6 1999 RESULTS: HGFR was expressed in RPE cells and was tyrosine-phosphorylated in response to HGF. Tyrosine 49-57 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 9-13 9722511-0 1998 Cooperative interaction between alpha- and beta-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses. Tyrosine 133-141 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 86-91 9722511-9 1998 These results indicate that HGF/beta binds to the c-Met/HGF receptor that is occupied by HGF/NK4 and induces receptor tyrosine phosphorylation and the subsequent biological activities of HGF. Tyrosine 118-126 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 50-55 9722511-9 1998 These results indicate that HGF/beta binds to the c-Met/HGF receptor that is occupied by HGF/NK4 and induces receptor tyrosine phosphorylation and the subsequent biological activities of HGF. Tyrosine 118-126 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 56-68 8906793-3 1996 A newly identified proline-rich domain of Gab1 is responsible for the binding of this protein to the tyrosine-phosphorylated bidentate docking site in c-Met. Tyrosine 101-109 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 151-156 9694510-9 1998 Addition of the tyrosine-phosphorylation inhibitor genistein inhibited HGF/SF-induced adhesion, supporting the idea that HGF/SF-induced effects are the result of signaling via the receptor c-MET after ligand binding. Tyrosine 16-24 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 189-194 9136843-10 1997 In young fetal stages, the c-Met immunoprecipitated 145-kilodalton band showed tyrosine phosphorylation after HGF stimulation. Tyrosine 79-87 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 27-32 9020068-5 1997 Cells treated with anti-Fas also exhibited increased tyrosine phosphorylation of the c-met growth factor receptor tyrosine kinase. Tyrosine 53-61 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 85-90 9524774-10 1997 Gab-1 binds to c-Met phosphorylated on tyrosine residues, but not to a number of other tyrosine kinases from different subfamilies. Tyrosine 39-47 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 15-20 7731718-2 1995 After ligand-induced tyrosine phosphorylation, the HGF receptor associates with the Shc adaptor, via the SH2 domain. Tyrosine 21-29 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 51-63 8601419-0 1996 Hepatocyte growth factor (HGF)-induced cell migration is negatively modulated by epidermal growth factor through tyrosine phosphorylation of the HGF receptor. Tyrosine 113-121 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 145-157 8601419-5 1996 HGF induced a rapid tyrosine phosphorylation of the HGF receptor in all these cell lines. Tyrosine 20-28 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 52-64 8601419-8 1996 The data presented here suggest that EGF negatively modulates the cellular response to HGF by increasing tyrosine phosphorylation of the HGF receptor in certain types of epithelial cells, e.g., MKN7 cells. Tyrosine 105-113 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 137-149 8398897-5 1993 The met/HGF/SF receptor of these cultured cells was constitutively phosphorylated on tyrosine residues. Tyrosine 85-93 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 8-23 8183564-7 1994 Site-directed mutagenesis of either of the two tyrosine residues involved in the positive regulation of the catalytic activity upon phosphorylation (Y1234 or Y1235 in the kinase domain of the HGF receptor), strongly impaired TRP-MET transforming potential. Tyrosine 47-55 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 192-204 8183564-8 1994 These data show that: (1) the truncated cytoplasmic HGF receptor has constitutive kinase activity and is oncogenic; (2) the first 39 amino acids of the juxtamembrane domain and (3) the regulatory tyrosines in the catalytic domain are required to unleash its transforming potential. Tyrosine 196-205 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 52-64 8294430-9 1994 Substitution of Ser985 by site-directed mutagenesis results in increased tyrosine phosphorylation of the receptor and abolishes down-modulation by protein kinase C. These data show that phosphorylation of Ser985 is a key mechanism for the negative regulation of HGF/SF receptor. Tyrosine 73-81 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 262-277 1327117-3 1992 We also examined their interactions with the c-met/HGF receptor by competition analysis and by analysis of levels of tyrosine phosphorylation. Tyrosine 117-125 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 45-50 7679901-0 1993 Tyrosine phosphorylation of phospholipase C gamma in c-met/HGF receptor-stimulated hepatocytes: comparison with HepG2 hepatocarcinoma cells. Tyrosine 0-8 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 53-58 7679901-0 1993 Tyrosine phosphorylation of phospholipase C gamma in c-met/HGF receptor-stimulated hepatocytes: comparison with HepG2 hepatocarcinoma cells. Tyrosine 0-8 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 59-71 1327117-9 1992 These results suggest that the heavy chain plays an important role in the interaction of hHGF with the c-met/HGF receptor and that the light chain is further required for the tyrosine phosphorylation of the c-met/HGF receptor. Tyrosine 175-183 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 213-225 1327117-7 1992 The relative levels of the tyrosine phosphorylation of the c-met/HGF receptor by these mutant proteins correlated well with the relative potencies of the biological activities when compared with that of the wild-type hHGF. Tyrosine 27-35 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 59-64 1327117-7 1992 The relative levels of the tyrosine phosphorylation of the c-met/HGF receptor by these mutant proteins correlated well with the relative potencies of the biological activities when compared with that of the wild-type hHGF. Tyrosine 27-35 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 65-77 1327117-9 1992 These results suggest that the heavy chain plays an important role in the interaction of hHGF with the c-met/HGF receptor and that the light chain is further required for the tyrosine phosphorylation of the c-met/HGF receptor. Tyrosine 175-183 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 207-212 31825565-1 2020 C-Met protein is a receptor tyrosine kinase of the hepatocyte growth factor (HGF), composed of an alpha and a beta chain. Tyrosine 28-36 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 0-5 1827664-5 1991 Nanomolar concentrations of highly purified HGF added to GTL-16 cells, which overexpress the c-MET receptor, enhanced the phosphorylation on tyrosine of the p190c-met kinase. Tyrosine 141-149 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 93-98 1674365-1 1991 The putative tyrosine kinase receptor encoded by the oncogene c-met is activated (tyrosine-phosphorylated in vivo) in the human gastric carcinoma cell line GTL-16. Tyrosine 13-21 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 62-67 2111905-0 1990 Protein kinase-c activation inhibits tyrosine phosphorylation of the c-met protein. Tyrosine 37-45 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 69-74 2111905-6 1990 Phospho-amino acid analysis of the c-met protein immunoprecipitated from [32P]orthophosphate-labelled GTL-16 cells shows that protein kinase-C activation leads to an increase in serine phosphorylation and to concomitant decrease in tyrosine phosphorylation. Tyrosine 232-240 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 35-40 34200450-7 2021 Further, we found that the ectopic expression of AEG-1 induced the tyrosine phosphorylation of c-Met, and NCL knockdown markedly reduced this AEG-1 mediated phosphorylation. Tyrosine 67-75 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 95-100 33520371-10 2021 Activation of the receptor tyrosine kinase c-MET positively correlates with poor prognosis for PDAC, and our previous study showed that nuclear c-MET can phosphorylate PARP1 at tyrosine 907 under ROS stimulation to promote DNA repair. Tyrosine 27-35 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 43-48 33520371-10 2021 Activation of the receptor tyrosine kinase c-MET positively correlates with poor prognosis for PDAC, and our previous study showed that nuclear c-MET can phosphorylate PARP1 at tyrosine 907 under ROS stimulation to promote DNA repair. Tyrosine 27-35 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 144-149 32028611-1 2020 c-Met is a receptor tyrosine kinase with no commercially available product despite being a pivotal target in cancer progression. Tyrosine 20-28 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 0-5 32070026-3 2020 The amplification of MET (hepatocyte growth factor receptor) compensates for the inhibition of epidermal growth factor receptor (EGFR) activity due to tyrosine kinase inhibitor (TKI), leading to TKI resistance. Tyrosine 151-159 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 26-59 31881189-1 2020 c-Met receptor is frequently overexpressed in hepatocellular carcinoma and thus considered as an attractive target for pharmacological intervention with small molecule tyrosine kinase inhibitors. Tyrosine 168-176 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 0-5 30692572-7 2019 (S)-crizotinib reduced tyrosine phosphorylation of c-MET and ErbB3 whereas TH588 induced a mitotic cell cycle arrest, which was not affected by adding ROS-modulating compounds. Tyrosine 23-31 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 51-56 31973231-1 2020 Anomalous changes of the cell mesenchymal-epithelial transition factor (c-Met) receptor tyrosine kinase signaling pathway play an important role in the occurrence and development of human cancers, including gastric cancer. Tyrosine 88-96 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 25-70 31973231-1 2020 Anomalous changes of the cell mesenchymal-epithelial transition factor (c-Met) receptor tyrosine kinase signaling pathway play an important role in the occurrence and development of human cancers, including gastric cancer. Tyrosine 88-96 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 72-77 31973231-2 2020 In this study, we designed and synthesized a novel peptide (CM 7) targeting the tyrosine kinase receptor c-Met, that can inhibit c-Met-mediated signaling in MKN-45 and U87 cells. Tyrosine 80-88 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 105-110 31832192-0 2019 Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer. Tyrosine 56-64 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 10-13 31584260-4 2019 Similarly, the tyrosine-protein kinase Met (cMET) is also overexpressed in PDAC (27-60%) and is a prognostic marker for poor survival. Tyrosine 15-23 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 44-48 31584260-7 2019 We previously developed a dual EGFR and cMET inhibitor (N19) that was able to inhibit tumor growth in nonsmall cell lung cancer models resistant to EGFR tyrosine kinase inhibitors (TKI). Tyrosine 153-161 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 40-44 31867280-1 2019 RON (recepteur d"origine nantais) and MET (hepatocyte growth factor receptor) are tyrosine kinase receptors. Tyrosine 82-90 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 43-76 30909596-8 2019 We demonstrate in vitro that c-MET phosphorylates four tyrosine residues localized mainly in the subunit-subunit interface of RAD51. Tyrosine 55-63 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 29-34 28179995-7 2017 We also demonstrate that SNX2 depletion causes an increase in hepatocyte growth factor receptor tyrosine phosphorylation and Erk1/2 signaling in cells. Tyrosine 96-104 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 62-95 30466782-7 2018 A comprehensive analysis of tyrosine phosphorylation in receptor tyrosine kinases in combination with small molecule chemical library screening revealed upregulated c-MET phosphorylation in this resistance cell line with elevated sensitivity to c-MET TKI (crizotinib) and PI3K/mTOR dual inhibitor (BEZ235). Tyrosine 28-36 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 165-170 30466782-7 2018 A comprehensive analysis of tyrosine phosphorylation in receptor tyrosine kinases in combination with small molecule chemical library screening revealed upregulated c-MET phosphorylation in this resistance cell line with elevated sensitivity to c-MET TKI (crizotinib) and PI3K/mTOR dual inhibitor (BEZ235). Tyrosine 28-36 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 245-250 30309648-10 2018 Excessive doses of HGF increased the phosphorylation of tyrosine residue 1003 involved in the ubiquitination of c-met, and phosphorylated c-met was diverted toward the proteasomal degradation pathway. Tyrosine 56-64 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 112-117 31949583-2 2018 c-Met, a receptor tyrosine kinase, transduces signals from extracellular growth factors. Tyrosine 18-26 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 0-5 24362531-7 2015 However, both sources of HGF increased the phosphorylation of c-MET on Tyr(1349), the multi-substrate docking site, by more than sixfold and led to activation of downstream signaling transducers. Tyrosine 71-74 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 62-67 27773821-0 2016 Tyrosine phosphorylation of RalGDS by c-Met receptor blocks its interaction with Ras. Tyrosine 0-8 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 38-43 27773821-6 2016 In this paper, we demonstrate a potential biochemical mechanism for such phenomena by showing that c-Met receptors promote the tyrosine phosphorylation of RalGDS at Y752 in its RBD, which blocks the binding of Ras to RalGDS. Tyrosine 127-135 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 99-104 23968581-6 2013 DIM decreased phosphorylation of the HGF receptor, c-Met, at tyrosines 1234 and 1235, indicating decreased activation of the receptor. Tyrosine 61-70 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 37-49 24634221-3 2014 HGF, in a dose-dependent manner, induced c-Met phosphorylation (Tyr-1234/1235, Tyr-1349, Ser-985, Tyr-1003, and Tyr-1313), activation of PI3k (phospho-Yp85) and Akt (phospho-Thr-308 and phospho-Ser-473) and potentiated lamellipodia formation and HLMVEC migration. Tyrosine 64-67 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 41-46 24634221-3 2014 HGF, in a dose-dependent manner, induced c-Met phosphorylation (Tyr-1234/1235, Tyr-1349, Ser-985, Tyr-1003, and Tyr-1313), activation of PI3k (phospho-Yp85) and Akt (phospho-Thr-308 and phospho-Ser-473) and potentiated lamellipodia formation and HLMVEC migration. Tyrosine 79-82 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 41-46 24634221-3 2014 HGF, in a dose-dependent manner, induced c-Met phosphorylation (Tyr-1234/1235, Tyr-1349, Ser-985, Tyr-1003, and Tyr-1313), activation of PI3k (phospho-Yp85) and Akt (phospho-Thr-308 and phospho-Ser-473) and potentiated lamellipodia formation and HLMVEC migration. Tyrosine 79-82 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 41-46 24634221-3 2014 HGF, in a dose-dependent manner, induced c-Met phosphorylation (Tyr-1234/1235, Tyr-1349, Ser-985, Tyr-1003, and Tyr-1313), activation of PI3k (phospho-Yp85) and Akt (phospho-Thr-308 and phospho-Ser-473) and potentiated lamellipodia formation and HLMVEC migration. Tyrosine 79-82 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 41-46 23952536-11 2013 Finally, we show that the Nanobody reduced phosphorylation of tyrosine residues in c-MET, MAPK, and Akt. Tyrosine 62-70 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 83-88 24081687-1 2013 Ephedrae herba suppresses hepatocyte growth factor-induced cancer cell motility by inhibiting tyrosine phosphorylation of the hepatocyte growth factor receptor, c-Met, and the PI3K/Akt pathway. Tyrosine 94-102 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 126-159 23624790-7 2013 Inhibition of LPS-mediated c-Met tyrosine (Y1003) phosphorylation and internalization by prior treatment with PHA-665752, inhibition of PKCalpha, or overexpression of c-MetY1003A mutant attenuated LPS-induced reduction of TER. Tyrosine 33-41 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 27-32 23624790-0 2013 Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function. Tyrosine 52-60 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 46-51 23624790-0 2013 Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function. Tyrosine 52-60 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 84-89 23288161-6 2013 Furthermore, cell-based ELISAs and kinase inhibitor studies showed that RCalphabeta induces phosphorylation of tyrosines 1234/1235 [corrected] and thus activation of cMet. Tyrosine 111-120 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 166-170 23624790-3 2013 Here, we demonstrate that lipopolysaccharide (LPS) treatment of human bronchial epithelial cells induced internalization of c-Met via phosphorylation at its tyrosine residue 1003. Tyrosine 157-165 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 124-129 23624790-6 2013 LPS-induced c-Met tyrosine 1003 phosphorylation, activation of PKCalpha, and c-Met internalization were, however, reversed by pretreatment of cells with LPA, which increased c-Met accumulation at cell-cell contacts. Tyrosine 18-26 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 12-17 22996389-3 2013 The sequential phosphorylation of tyrosine residues, from c-Met kinase domain to multidocking regions, is required for HGF-signalling transduction. Tyrosine 34-42 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 58-63 22996389-4 2013 Herein, we provide evidence that the disconcerted activation of c-Met tyrosine regions fails to induce biological functions. Tyrosine 70-78 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 64-69 21316260-5 2011 Mutations and amplifications in molecules related to receptor tyrosine signalling, such as EGFR, ErbB2, c-Met, c-Kit, VEGFR, PI3K, and PTEN are only some of the alterations known to contribute to the development of lung cancer. Tyrosine 62-70 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 104-109 21777671-5 2011 We demonstrated that these cells express a functional c-MET, and cell exposure to NK1 induces the phosphorylation of tyrosines 1313/1349/1356 residues of c-MET which provide docking sites for signaling molecules. Tyrosine 117-126 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 54-59 21777671-5 2011 We demonstrated that these cells express a functional c-MET, and cell exposure to NK1 induces the phosphorylation of tyrosines 1313/1349/1356 residues of c-MET which provide docking sites for signaling molecules. Tyrosine 117-126 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 154-159 21734462-8 2011 However, vitamin K1 enhanced sorafenib-induced c-Met phosphorylation at Tyr-1349, a DEP-1 protein phosphatase acting site, and consequently induced phosphorylation of PI3K-Akt. Tyrosine 72-75 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 47-52 21423210-4 2011 EGFR ligands induce accumulation of activated c-Met, which begins at 8 h and continues for 48 h. This effect is accompanied by an increase in c-Met expression and phosphorylation of critical c-Met tyrosine residues without activation of mitogen-activated protein kinase (MAPK) or Akt. Tyrosine 197-205 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 46-51 21283737-9 2011 In glioma cells, autocrine activation of c-MET by HGF-c-MET increased basal levels of c-MET phosphorylation at tyrosine (Tyr) 1003. Tyrosine 111-119 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 41-46 21283737-9 2011 In glioma cells, autocrine activation of c-MET by HGF-c-MET increased basal levels of c-MET phosphorylation at tyrosine (Tyr) 1003. Tyrosine 111-119 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 54-59 21283737-9 2011 In glioma cells, autocrine activation of c-MET by HGF-c-MET increased basal levels of c-MET phosphorylation at tyrosine (Tyr) 1003. Tyrosine 111-119 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 54-59 21283737-9 2011 In glioma cells, autocrine activation of c-MET by HGF-c-MET increased basal levels of c-MET phosphorylation at tyrosine (Tyr) 1003. Tyrosine 121-124 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 41-46 21283737-9 2011 In glioma cells, autocrine activation of c-MET by HGF-c-MET increased basal levels of c-MET phosphorylation at tyrosine (Tyr) 1003. Tyrosine 121-124 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 54-59 21283737-9 2011 In glioma cells, autocrine activation of c-MET by HGF-c-MET increased basal levels of c-MET phosphorylation at tyrosine (Tyr) 1003. Tyrosine 121-124 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 54-59 21163258-0 2011 An adjacent arginine, and the phosphorylated tyrosine in the c-Met receptor target sequence, dictates the orientation of c-Cbl binding. Tyrosine 45-53 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 61-66 21163258-1 2011 Previously, we have demonstrated that the tyrosine phosphorylated hepatocyte growth factor receptor (Met) binds to the c-Cbl phosphotyrosine-recognition, tyrosine kinase binding (TKB) domain in a reverse orientation compared to other c-Cbl binding partners. Tyrosine 42-50 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 66-99